U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C18H31NO4.C4H4O4
Molecular Weight 766.9582
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BISOPROLOL FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC2=CC=C(COCCOC(C)C)C=C2

InChI

InChIKey=VMDFASMUILANOL-WXXKFALUSA-N
InChI=1S/2C18H31NO4.C4H4O4/c2*1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4;5-3(6)1-2-4(7)8/h2*5-8,14-15,17,19-20H,9-13H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+

HIDE SMILES / InChI

Molecular Formula C18H31NO4
Molecular Weight 325.443
Charge 0
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
8.8 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIAC

Cmax

ValueDoseCo-administeredAnalytePopulation
52 μg/L
10 mg 1 times / day steady-state, oral
BISOPROLOL plasma
Homo sapiens
40.37 ng/mL
10 mg single, oral
BISOPROLOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
661 μg × h/L
10 mg 1 times / day steady-state, oral
BISOPROLOL plasma
Homo sapiens
609.8 ng × h/mL
10 mg single, oral
BISOPROLOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
10 mg 1 times / day steady-state, oral
BISOPROLOL plasma
Homo sapiens
11.07 h
10 mg single, oral
BISOPROLOL plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
10 mg 1 times / day steady-state, oral
BISOPROLOL plasma
Homo sapiens
70%
10 mg single, oral
BISOPROLOL plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
2.5 to 40 mg once-daily dose
Route of Administration: Oral
In Vitro Use Guide
Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test and in the mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43-1300 µg/mL.
Substance Class Chemical
Record UNII
UR59KN573L
Record Status Validated (UNII)
Record Version